You searched for side effects - Page 32 of 311

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Posted by Medivizor on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Posted by Medivizor on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by Medivizor on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Posted by Medivizor on Dec 4, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma. The data showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) was the best treatment regimen in significantly improving overall survival and survival without cancer worsening in these patients. Some...

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Posted by Medivizor on Dec 4, 2022 in Infertility | 0 comments

In a nutshell This study evaluated whether the administration of growth hormone (GH) improves endometrial function and reproductive outcomes in women undergoing in vitro fertilization (IVF) cycles. The data showed that GH administration significantly improved endometrial function and increased the live birth and clinical pregnancy rate in these...

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Posted by Medivizor on Dec 4, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Posted by Medivizor on Dec 4, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo)...

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

$Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.$

Posted by Medivizor on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Posted by Medivizor on Nov 22, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with tiragolumab (MTIG7192A) as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The data showed that tiragolumab plus atezolizumab significantly improved the objective response rate and the survival without...

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Posted by Medivizor on Nov 22, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients. Some...

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by Medivizor on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Is dorzagliatin an effective add-on treatment to metformin in patients with type 2 diabetes?

Posted by Medivizor on Nov 5, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of adding dorzagliatin (HMS552) to metformin therapy in patients with type 2 diabetes (T2D) with inadequately controlled blood glucose (sugar) while using metformin (Glucophage) alone. The data showed effective blood glucose control, good tolerance, and safety in patients...

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Is dorzagliatin an effective add-on treatment to metformin in patients with type 2 diabetes?

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email